Cytokinetics aims for over 50% new patient share for MYQORZO by end of 2026 as global commercial launch accelerates
Source: SeekingAlpha
2026-02-25 01:08:32 ET
More on Cytokinetics
- Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
- Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Cytokinetics: Small Label Differences With Big Commercial Stakes
- Cytokinetics Q4 2025 Earnings Preview
- Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy
Read the full article on Seeking Alpha
For further details see:
Cytokinetics aims for over 50% new patient share for MYQORZO by end of 2026 as global commercial launch accelerates
Cytokinetics Incorporated
NASDAQ: CYTK
CYTK Trading
-0.91% G/L:
$61.15 Last:
204,181 Volume:
$62.24 Open:
CYTK Latest News
March 09, 2026 02:38:32 pm
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
February 24, 2026 04:00:00 pm
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
CYTK Stock Data
$7,892,201,167
118,963,776
0.07%
158
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
